Proactive Investors - Run By Investors For Investors

Imugene Ltd appoints Leslie Chong to chief executive officer

Imugene Ltd (ASX:IMU) has promoted Leslie Chong to the position of chief executive officer, as the company prepares for the critical milestone of dosing the patients in the gastric cancer Phase 1b/2 clinical trial in Asia.
Imugene Ltd appoints Leslie Chong to chief executive officer
Imugene Ltd appoints Leslie Chong to chief executive officer

Chong joined IMU in September 2015 from the pharmaceutical giant, Genentech, in San Francisco where she had a distinguished career across many aspects of drug development.

Imugene is a clinical stage immuno-oncology company, with its lead product being HER-Vaxx, a B Cell peptide vaccine for the treatment of gastric cancer.

The company is also developing mimotope-based immunotherapies against validated and new oncology targets.

View full IMU profile View Profile

Imugene Ltd Timeline

Related Articles

Once the phase III trial is completed, Futura plans to either sell off the asset or find a partner
September 26 2018
The pharma group expects to dose the first patient in the Phase III trial of its MED2002 erectile dysfunction treatment within the next month
cannabis
February 28 2019
The company is a leader for dried flower vaporizers, and a pioneer in cannabis telemedicine and AI technologies
1538160791_petri-dishes.jpg
September 29 2018
The biotech group revealed it had brought in $9.1mln via an oversubscribed placing

© Proactive Investors 2019

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use